Newsfeeds Archive - Page 18 of 56

2 minute read

Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change

July 5, 4:46 PM

Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to

DMTTF

2 minute read

Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next

By Lara Goldstein

July 5, 1:53 PM

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic.

AWKNF

2 minute read

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital

By Lara Goldstein

July 5, 1:20 PM

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist

ATAI

4 minute read

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More

By Lara Goldstein

July 4, 10:21 AM

World's Largest Psychedelics Conference Boasts 12K Attendees

BETRF

3 minute read

Psyched: $75M In Federal Funds, Gov. Polis Opens MAPS Event, CNN’s Show, Dock Ellis’ LSD Pitch & More

By Lara Goldstein

July 3, 5:01 PM

Federal Psychedelics: $75M Grant Program

AWKNF

3 minute read

Burning Man CEO Learned ‘So Much’ About Psychedelics In BRC: ‘We’re Here For The Love’

By Lara Goldstein

June 30, 11:28 AM

Burning Man CEO Marian Goddell attended Psychedelic Science 2023 in Denver, where she spoke with MAPS strategic initiatives officer Lia

TSLA

2 minute read

Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses

By Lara Goldstein

June 29, 2:55 PM

UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates. Highlights:

DMTTF

3 minute read

Reunion Neuroscience’s Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3

By Lara Goldstein

June 29, 1:22 PM

Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ: REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report:

FTHWF

2 minute read

This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches

By Lara Goldstein

June 28, 6:27 PM

Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130.

LOBEF

1 minute read

BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives

By Lara Goldstein

June 28, 3:01 PM

Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S.

BETRF